Skip to main content

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

 PHARMACOTHERAPY: 

Medications classifications include:

  1.  Sulfonyl Urea's
  2. Nonsylfonylurea Secretagogues (a-Glinides)
  3. Biguanides
  4. Thiazolidinediones
  5. a-Glucosidase Inhibitors
  6. Dipeptidyl Peptidase-4 Inhibitors (Gliptins)
  7. Sodium-glucose co-transporter (SGLT) Inhibitors 
  8. Central-Acting Dopamine Agonists
  9. Bile Acid Sequestrants
  10. Insulin therapy

5. a-GLUCOSIDASE INHIBITORS

  • Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States.

Mechanism of Action:

  • An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels.


Therapy:

As a monotherapy, a-glucosidase inhibitors primarily reduce post-prandial glucose excursions. 

Clinical Use:

FPG concentrations have been decreased by 40-50mg/dL and A1c levels are decreased by 0.3%-1%.

Adverse Effects:

  • High incidences of GI Upset such as Flatulence, abdominal discomfort, and diarrhea. 
  • GI effects occur as a result of intestinal bacteria in the distal gut metabolizing undigested carbohydrates and producing carbon dioxide and methane gas.

Contraindications:

Contraindicated in patients with;

  • short bowel syndrome
  • Inflammatory Bowel Disease
  • In patients with serum creatinine greater than 2mg/dL.


6. DIPEPTIDYL PEPTIDASE-4 INHIBITORS (GLIPTINS)

  • Drugs included mostly are Sitagliptin, Saxagliptin and Linagliptin.
  • These are approved as adjunct to diet and exercise to improve glycemic control in adults with T2DM.

Mechanism of Action:

  • These agents lower the blood glucose levels by inhibiting DPP-4; the enzyme that degrade endogenous GLP-1(Incretins). DPP-4 Inhibitors increase the amount of endogenous GLP-1.


Clinical Use:

  • Used primarily to decrease postprandial blood glucose levels.
  • Typical A1c reductions are 0.7-1%.

Adverse effects:

  • Headache
  • Nasopharyngitis
  • Hypoglycemia

Dose Adjustments:

Sitagliptin: Dosage adjustments for 50-25mg/day are recommended for patients with moderate and severe renal impairment, respectively.

Saxagliptin: should be dosed at 2.5mg/day with creatinine clearance less than 50ml/min or if strong CYP3A4/5 inhibitors are being used concomitantly.

Linagliptin: is a substrate of CYP3A4 is dosed at 5mg/day and requires no adjustment for renal or hepatic impairment.

Labels:

Comments

Post a Comment

Popular posts from this blog

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD) ...
Post a Comment
Read more

Drug-Induced Nephrotoxicity!

 DRUG-INDUCED NEPHROTOXICITY Drug-Induced Nephrotoxicity is increasingly recognized as a significant contributor to kidney disease including Acute Kidney Injury (KI) and chronic kidney disease (CKD). Nephrotoxicity has a wide spectrum, reflecting damage to different nephron segments based upon individual drug-mechanisms. 1. ACE-INHIBITORS: ACE-Inhibitors are frequently associated with Proteinuria and Renal Insufficiency. The prevalence of Proteinuria in Captopril treated patient is estimated to be 1%. The risk of Renal Insufficiency is greater with long-acting ACE Inhibitors such as Lisinopril or Enalapril than with Captopril. Immune complex glomerulopathy is a major contribute to ACE Inhibitor nephrotoxicity. Predisposing factors include: Hyponatremia Diuretic therapy Pre-existing renal impairment Congestive Heart Failure (CHF) Diabetes Mellitus Recovery of renal function usually follows ACE-Inhibitor discontinuation. 2. CEPHLOSPORIN: The cephalosporin antibiotics are capable of...
Post a Comment
Read more